34.6% of patients received chemotherapy, whereas anti-HER2 therapy (17% of patients), anti-hormone therapy (15% of patients) and CDK4/6-inhibtor therapy (18% of patients) were the other most common anti-cancer therapies. The gene discussed is ERBB2; the disease is cancer.